Novel fluoronucleoside analog NCC inhibits lamivudine-resistant hepatitis B virus in a hepatocyte model

Antiviral drug resistance is the most important factor contributing to treatment failure using nucleos(t)ide analogs such as lamivudine for chronic infection with hepatitis B virus (HBV). Development of a system supporting efficient replication of clinically resistant HBV strains is imperative, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jingmin, Wang, Yafeng, Peng, Youmei, Qin, Chongzhen, Liu, Yixian, Li, Jingjing, Jiang, Jinhua, Zhou, Yubing, Chang, Junbiao, Wang, Qingduan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425639/
https://www.ncbi.nlm.nih.gov/pubmed/30586543
http://dx.doi.org/10.1016/j.bjid.2018.11.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425639/
https://www.ncbi.nlm.nih.gov/pubmed/30586543
http://dx.doi.org/10.1016/j.bjid.2018.11.005

Ejemplares similares